Charles River Laboratories International, Inc. Profile and SWOT Analysis

Charles-River-Laboratories-International-Inc

Report Name: Charles River Laboratories International, Inc. Profile – Overview, History, SWOT Analysis, Products/Services, Facts, Financials, Key Executives, Competitors, Tech Intelligence, IT Outsourcing, IT Management, Recent Developments and Strategy Evaluation

Charles River Laboratories International, Inc. Report – Publisher: Research Cosmos

Price Scheme of the Report:

Single User License – USD 150

Team License – USD 175

Corporate License – USD 250

Charles River Laboratories International, Inc.– Business Description:

Charles River Laboratories International, Inc. (CRL or ‘the company’) is engaged in providing research models required in research and development of new drugs, devices and therapies. The company offers its products and services to global pharmaceutical companies, biotechnology companies, government agencies, hospitals and academic institutions throughout the world. The company operates in the US, Canada, Japan, Europe and other regions of the world. It operates about 75 facilities in 23 countries worldwide.

The company’s operations are divided into three business segments: Discovery and Safety Assessment (DSA), Research Models and Services (RMS), and Manufacturing Support (Manufacturing).

The DSA segment of CRL offers discovery and safety assessment services, both regulated and non-regulated, which include both in vitro and in vivo studies, supporting laboratory services, and strategic non-clinical consulting and program management to support product development. DSA segment offers services in two categories: discovery services, and safety assessment.

The discovery services business category offers discovery services ranging from identification of a novel druggable target, followed by high-throughput screening and medical chemistry, through delivery of non-clinical drug and therapeutic candidates ready for safety assessment. Early discovery and in vivo discovery businesses of CRL are integrated into discovery services business category.

Safety assessment business category offers a range of discovery and safety assessment studies required for regulatory submission on a global basis. The safety assessment facilities includes bioanalysis, drug metabolism and pharmacokinetics; safety pharmacology; toxicology; and pathology services.

In FY2016, the DSA segment reported revenues of $836.6 million, which accounted for 49.8% of the company’s total revenue.

The company’s RMS segment supplies research models to the drug development industry. It offers services in two categories: research models and RMS.

Research models business category is comprised of the commercial production and sale of research models, principally purpose-bred rats and mice for use by researchers. The company provides its rodent models to numerous clients around the world, including most pharmaceutical companies, a range of biotechnology companies, and many government agencies, hospitals, and academic institutions.

In RMS business category, there are three services offered by the company. These are genetically engineered models and services (GEMS), insourcing solutions (IS), and research animal diagnostic services (RADS).

Under GEMS, the company breeds and maintains research models purchased or purposefully created by its clients for biomedical research activities. CRL provides these services to clients around the world ranging from pharmaceutical and biotechnology companies to hospitals and universities.

Under IS, the company manages research operations (including recruitment, training, staffing, and management services) for government entities, academic organizations, and commercial clients. Under RADS, the company monitors and analyzes the health profiles of research models and cell lines used by its clients.

In FY2016, the RMS segment reported revenues of $494 million, which accounted for 29.4% of the company’s total revenue.

The company’s Manufacturing Support (Manufacturing) services has three business categories: microbial solutions, biologics testing solutions, and avian vaccine services.

The microbial solutions business category provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceutical and consumer products. Biologics testing solutions business category performs specialized testing of biologics frequently outsourced by global pharmaceutical and biotechnology companies. Under avian vaccine services, CRL supplies SPF (specific pathogen free) fertile chicken eggs and chickens.

In FY2016, the Manufacturing segment reported revenues of $350.8 million, which accounted for 20.8% of the company’s total revenue.

Geographically, the company classifies its operations into five segments, namely the US, Canada, Japan, Europe, and other Non-US regions. In FY2016, the US segment accounted for 50.6% of the company’s total revenues, followed by Canada with 11.6%; Japan with 2.8%; Europe with 31%; and other Non-US regions with 4%.

Scope of the Report:

About the Company: Historical Details, Current Ownership Structure and basic overview of Charles River Laboratories International, Inc in terms of revenue, net income, and operating income.

Financials: Details about Charles River Laboratories International, Inc listing status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.

Products/Services: Listing of the company’s entire portfolio along with the description of individual products/services providing a clear picture of their target audience.

Company SWOT Analysis: Outlines Atea ASA.’s strengths, weaknesses, and opportunities and threats facing the company.

Recent Developments: Showcases Atea ASA.’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.

Strategic Evaluation: This section provides an overview of Atea ASA.’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.

Technology Landscape: Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken by the company at present along with outlook.

Key Questions Answered

What domain does Charles River Laboratories International, Inc operate and what are key points about it?

What is the product/service portfolio of Atea ASA.?

How has Charles River Laboratories International, Inc performed financially from 2013?

How does Charles River Laboratories International, Inc rank among its peers in terms of revenue and market share?

What are Charles River Laboratories International, Inc strengths and weaknesses and what opportunities and threats do it face?

What are Atea ASA.’s main growth strategies and how successful has the company been at implementing them?

What is the in-house technical capability of Atea ASA.? Where does it procure/outsource it?

Reasons to buy

Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own

Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at a very competitive cost

12 hour delivery time fulfilling your urgent requests as per your requirement

On-demand customization options that can completely cater to your needs by focusing the report on given specifics

For More Information, Get Sample of the report: Request Sample

Got Some Questions? Inquire Here: Inquire Before Buying

Get This Report: Purchase Now

For More Details, Contact Provider Directly:

Kevin Stewart
Sales Manager
Research Cosmos
kevin@researchcosmos.com
+1 888 709 8757

Be the first to comment

Leave a Reply